Detailed information for compound 1973840

Basic information

Technical information
  • Name: Unnamed compound
  • MW: 560.707 | Formula: C31H36N4O4S
  • H donors: 1 H acceptors: 3 LogP: 4.39 Rotable bonds: 8
    Rule of 5 violations (Lipinski): 2
  • SMILES: COc1ccc(cc1C)C(=O)N1CCC[C@@H]1c1cccc(c1)C(=O)Nc1nc2c(s1)C[C@H](CC2)N1CCOCC1
  • InChi: 1S/C31H36N4O4S/c1-20-17-23(8-11-27(20)38-2)30(37)35-12-4-7-26(35)21-5-3-6-22(18-21)29(36)33-31-32-25-10-9-24(19-28(25)40-31)34-13-15-39-16-14-34/h3,5-6,8,11,17-18,24,26H,4,7,9-10,12-16,19H2,1-2H3,(H,32,33,36)/t24-,26+/m0/s1
  • InChiKey: RJYYFRDVKYGGJW-AZGAKELHSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

No synonyms found for this compound

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens Rho-associated, coiled-coil containing protein kinase 2 Starlite/ChEMBL No references

Predicted pathogen targets for this compound

By orthology
Species Potential target Known druggable target/s Ortholog Group
Schistosoma mansoni serine/threonine protein kinase Get druggable targets OG5_131020 All targets in OG5_131020
Brugia malayi Protein kinase domain containing protein Get druggable targets OG5_131020 All targets in OG5_131020
Onchocerca volvulus Get druggable targets OG5_131020 All targets in OG5_131020
Echinococcus granulosus rho-associated protein kinase 1 Get druggable targets OG5_131020 All targets in OG5_131020
Onchocerca volvulus Get druggable targets OG5_131020 All targets in OG5_131020
Schistosoma japonicum Rho-associated protein kinase 1, putative Get druggable targets OG5_131020 All targets in OG5_131020
Loa Loa (eye worm) AGC/DMPK/ROCK protein kinase Get druggable targets OG5_131020 All targets in OG5_131020
Schistosoma japonicum IPR002219,Protein kinase C, phorbol ester/diacylglycerol binding,domain-containing Get druggable targets OG5_131020 All targets in OG5_131020
Echinococcus multilocularis rho associated protein kinase Get druggable targets OG5_131020 All targets in OG5_131020
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Trichomonas vaginalis replication factor A 1, rfa1, putative 0.0154 0.2502 1
Leishmania major replication factor A, 51kDa subunit, putative 0.0074 0.0976 0.5
Entamoeba histolytica replication factor A protein 1, putative 0.0066 0.0832 0.5
Onchocerca volvulus 0.0176 0.2928 1
Plasmodium falciparum replication protein A1, large subunit 0.0074 0.0976 0.5
Loa Loa (eye worm) AGC/DMPK/ROCK protein kinase 0.0546 1 1
Giardia lamblia Hypothetical protein 0.0022 0 0.5
Trichomonas vaginalis replication factor A 1, rfa1, putative 0.0146 0.2358 0.9053
Loa Loa (eye worm) replication factor A 73 kDa subunit 0.0154 0.2502 0.2378
Trichomonas vaginalis replication factor A 1, rfa1, putative 0.0154 0.2502 1
Echinococcus granulosus rho-associated protein kinase 1 0.0176 0.2928 1
Echinococcus multilocularis rho associated protein kinase 0.0176 0.2928 1
Plasmodium vivax replication protein A1, large subunit, putative 0.0074 0.0976 0.5
Onchocerca volvulus 0.0175 0.2921 0.9903
Toxoplasma gondii replication factor-a protein 1 (rpa1) subfamily protein 0.0074 0.0976 1
Brugia malayi replication factor A 73 kDa subunit 0.0154 0.2502 0.2378
Trypanosoma cruzi Replication factor A protein 1 0.0074 0.0976 0.5
Schistosoma mansoni serine/threonine protein kinase 0.0176 0.2928 1
Trypanosoma brucei Replication factor A protein 1 0.0074 0.0976 0.5

Activities

Activity type Activity value Assay description Source Reference
IC50 (binding) = 7.8 nM BindingDB_Patents: Luciferin-Luciferase Assay. The activity of ROCKII (1-543) kinase was measured utilizing Cambrex PKLight ATP Detection Reagent, a homogeneous assay technology using luciferin-luciferase to quantify residual ATP. The assay was performed in 384-well low-volume, white, non- binding surface micro titer plates (Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl2, 50 mM KC1, 0.2% BSA, 0.01% CHAPS, 100 uM Na3VO4 and 0.5 mM DTT. Test compounds, dissolved in neat DMSO at 500 ug/mL, were serially diluted for dose response for a final starting concentration of 3 ug/mL in 1% DMSO of assay buffer. ROCKII (1-543) (62,408Da) was diluted in assay buffer to a final concentration of 7.5 nM in a total volume of 15 ul. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing no kinase. ChEMBL. No reference
IC50 (binding) = 9.7 nM BindingDB_Patents: IMAP Assay. This assay is performed using FAM S6 substrate peptide (Catalogue #R7184) and IMAP FP Screening Express Kit detection reagents from Molecular Devices (Sunnyvale, CA) in IMAP kinase reaction buffer (Tris-HCl, pH 7.2, 10 mM MgC12 , 0.05% NaN3, 0.1% phosphate-free BSA) containing 1 mM DTT. Test compounds dissolved in neat DMSO at 0.3 mg/mL are serially diluted 1 to 3 for concentration response in 100% DMSO. The DMSO serial dilutions are further diluted 33.33-fold in kinase reaction buffer, and 10 μL of this buffer dilution is transferred to Corning black 96-well half area NBS plates for a final top concentration of 3 ug/mL in 1% DMSO. 10 aliquot of 3 nM ROCKII (1-543) diluted in kinase reaction buffer is added to each assay well for a final concentration of 1 nM kinase. 10 uL of a mixture of 600 nM FAM S6 peptide and 300 uM ATP diluted in kinase reaction buffer is added to each well for a final concentration of 200 nM peptide and 100 uM ATP. ChEMBL. No reference

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

No literature references available for this target.

If you have references for this compound, please enter them in a user comment (below) or Contact us.